Latest Articles

Publication Date
Merck's endometrial cancer therapy fails trial - ETHealthWorld

Merck's endometrial cancer therapy fails trial ETHealthWorld

Published: May 9, 2024, 7 a.m.
Excessive endometrial PlGF- Rac1 signalling underlies endometrial cell stiffness linked to pre-eclampsia - Nature.com

Excessive endometrial PlGF- Rac1 signalling underlies endometrial cell stiffness linked to pre-eclampsia Nature.com

Published: May 4, 2024, 7 a.m.
After an Endometrial Cancer Diagnosis, A Nurse Seizes a Chance to Soar - Health Matters

After an Endometrial Cancer Diagnosis, A Nurse Seizes a Chance to Soar Health Matters

Published: May 3, 2024, 7 a.m.
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials - The Lancet

Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials The Lancet

Published: April 30, 2024, 7 a.m.
Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer - The Lancet

Combining the prognostic role of age with molecular advances in the understanding of endometrial cancer The Lancet

Published: April 30, 2024, 7 a.m.
Early GnRH-agonist therapy does not negatively impact the endometrial repair process or live birth rate - Frontiers

Early GnRH-agonist therapy does not negatively impact the endometrial repair process or live birth rate Frontiers

Published: April 29, 2024, 7 a.m.
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer - OncLive

Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer OncLive

Published: April 24, 2024, 7 a.m.
GSK's endometrial cancer drug receives FDA approval - ShareCast

GSK's endometrial cancer drug receives FDA approval ShareCast

Published: April 24, 2024, 7 a.m.
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - PR Newswire

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting PR Newswire

Published: April 24, 2024, 7 a.m.
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - Investor Relations | Karyopharm Therapeutics

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting Investor Relations | Karyopharm Therapeutics

Published: April 24, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!